Ullah Aftab, Shabil Muhammad, Abdulsamad Saud A, Jan Asif, Naeem Abdulghani A, Ullah Haseen, Khattak Mudassir
Department of Pharmacy, University of Peshawar, Peshawar, Pakistan.
Department of Pharmacy, Abasyn University Peshawar, Peshawar, Pakistan.
Open Forum Infect Dis. 2025 Mar 11;12(4):ofaf131. doi: 10.1093/ofid/ofaf131. eCollection 2025 Apr.
Antibiotic resistance to is a significant threat to public health globally, particularly in low- and middle-income countries such as Pakistan. This study reviews the existing literature to determine the pooled prevalence of antibiotic resistance among and strains across Pakistan in the past decade, including the emergence of extended-spectrum β-lactamase.
Six databases were searched for studies published from January 2014 to December 2024. Studies were screened for relevance, and data were extracted on antibiotic susceptibility among human and isolates. Their quality was assessed per the Joanna Briggs Institute checklist. A random effects model was employed by R statistical software (version 4.4) to calculate the pooled resistance rates.
Thirty-one studies met the inclusion criteria after full-text screening. The analysis revealed significant resistance rates to commonly used antibiotics for , including nalidixic acid (92%; 95% CI, 88%-95%), ampicillin (80%; 95% CI, 66%-89%), ciprofloxacin (64%; 95% CI, 48%-77%), azithromycin (7%; 95% CI, 3%-16%), and meropenem (2%; 95% CI, 1%-3%), with notable variations across cities, and for , such as nalidixic acid (91%; 95% CI, 82%-96%), ampicillin (34%; 95% CI, 21%-50%), ciprofloxacin (51%; 95% CI, 25%-77%), azithromycin (4%; 95% CI, 1%-12%), and meropenem (2%; 95% CI, 1%-5%). In , 29% and 25% of patients had multidrug resistance (95% CI, 21%-41%) and extensive drug resistance (95% CI, 12%-44%), respectively; corresponding rates for were 9% (95% CI, 2%-28%) and 2% (95% CI, 1%-7%).
The findings revealed the alarming prevalence of antibiotic-resistant in Pakistan and the need for updated treatment guidelines. Public health strategies must focus on improving antibiotic use and developing alternative treatment options to mitigate the rising threat of resistant strains. Continued research, policy intervention, and national and international cooperation are essential to safeguard public health and ensure effective management of enteric fever.
抗生素耐药性对全球公共卫生构成重大威胁,在巴基斯坦等低收入和中等收入国家尤为如此。本研究回顾现有文献,以确定过去十年巴基斯坦各地沙门氏菌和志贺氏菌菌株中抗生素耐药性的合并流行率,包括超广谱β-内酰胺酶的出现情况。
检索了六个数据库,查找2014年1月至2024年12月发表的研究。筛选研究的相关性,并提取人类沙门氏菌和志贺氏菌分离株的抗生素敏感性数据。根据乔安娜·布里格斯研究所的清单评估其质量。使用R统计软件(版本4.4)采用随机效应模型计算合并耐药率。
经过全文筛选,31项研究符合纳入标准。分析显示,沙门氏菌对常用抗生素有显著耐药率,包括萘啶酸(92%;95%置信区间,88%-95%)、氨苄西林(80%;95%置信区间,66%-89%)、环丙沙星(64%;95%置信区间,48%-77%)、阿奇霉素(7%;95%置信区间,3%-16%)和美罗培南(2%;95%置信区间,1%-3%),不同城市存在显著差异;志贺氏菌的情况如萘啶酸(91%;95%置信区间,82%-96%)、氨苄西林(34%;95%置信区间,21%-50%)、环丙沙星(51%;95%置信区间,25%-77%)、阿奇霉素(4%;95%置信区间,1%-12%)和美罗培南(2%;95%置信区间,1%-5%)。在沙门氏菌中,分别有29%和25%的患者有多药耐药(95%置信区间,21%-41%)和广泛耐药(95%置信区间,12%-44%);志贺氏菌的相应比例分别为9%(95%置信区间,2%-—28%)和2%(95%置信区间,1%-7%)。
研究结果揭示了巴基斯坦抗生素耐药性沙门氏菌的惊人流行率以及更新治疗指南的必要性。公共卫生策略必须侧重于改善抗生素使用情况,并开发替代治疗方案,以减轻耐药性沙门氏菌菌株不断上升的威胁。持续的研究、政策干预以及国家和国际合作对于保障公共卫生和确保有效管理伤寒至关重要。